GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » Cash And Cash Equivalents

Shandong Wohua Pharmaceutical Co (SZSE:002107) Cash And Cash Equivalents : ¥456.7 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co Cash And Cash Equivalents?

Shandong Wohua Pharmaceutical Co's quarterly cash and cash equivalents increased from Sep. 2023 (¥364.06 Mil) to Dec. 2023 (¥401.10 Mil) and increased from Dec. 2023 (¥401.10 Mil) to Mar. 2024 (¥456.69 Mil).

Shandong Wohua Pharmaceutical Co's annual cash and cash equivalents declined from Dec. 2021 (¥326.84 Mil) to Dec. 2022 (¥278.29 Mil) but then increased from Dec. 2022 (¥278.29 Mil) to Dec. 2023 (¥401.10 Mil).


Shandong Wohua Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Shandong Wohua Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Wohua Pharmaceutical Co Cash And Cash Equivalents Chart

Shandong Wohua Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 300.69 494.43 326.84 278.29 401.10

Shandong Wohua Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309.85 332.06 364.06 401.10 456.69

Shandong Wohua Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Shandong Wohua Pharmaceutical Co  (SZSE:002107) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Shandong Wohua Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Traded in Other Exchanges
N/A
Address
Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011
Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.
Executives
Zhao Jun Director
Liu Wen Yi Supervisors
Zhang Fa Zhong Supervisors
Zhang Ge Director
Ma Xing Chen Supervisors
Tian Kai Ji Directors, executives
Kong Xian Jun Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines